NMD-VCell Neuromuscular Virtual Cell Research Platform Neuromuscular Virtual Cell Platform · Evidence → perturbation → experiment → outcome NMD = neuromuscular disorders

Evidence Release 2026.08DMD context observedDMD candidate-conditioned prediction locked

View scientific status
Evidence freeze: 3 August 2026 P59 hold · scorer failure retained · no target score NAR working package · 6 main + 31 supplementary figures Resource: v1.2.0-measured-dmd-evidence Schema: 1.1 Open platform state → Open Trust Center → Open evidence dashboard → Open claim registry → Open release status →

Disease evidence coverage

Compare evidence depth without naming a disease winner.

States are categorical contracts. MISSING is not zero, and a cell never substitutes for the underlying statistical unit or effect estimate.

Evidence dimensionDMDFSHDDM1SMA
Etiologic anchorMEASUREDINDUCEDCORRECTEDMEASURED
Patient/disease stateMEASUREDMEASUREDMEASUREDMEASURED
Causal induction/correctionCORRECTEDINDUCEDCORRECTEDCORRECTED
Intervention/perturbationPERTURBEDMEASUREDMISSINGPERTURBED
Independent replicationMEASUREDMISSINGMEASUREDMEASURED
Prospective candidate validationMISSINGMISSINGMISSINGMISSING

Cells are typed evidence states, not numerical scores; MISSING is not zero and no row is ranked.

Measured reanalysis

Patient state, causal/intervention axis and null results.

FSHD, DM1 and SMA measured evidence with positive, null and directional findings.

Analysis-plan-frozen single-cell layer

FSHD injury and SMA organoid states are compared at the correct biological-unit level.

Open synchronized figure manifest
FSHD and SMA analysis-plan-frozen single-cell analyses with biological-line-level effects and explicit small-n boundaries.

The combined view is a state-localization layer, not a pooled cross-disease score. No therapeutic candidate is promoted to validated status. The two disease vectors are hosted separately; the combined standalone SVG/PDF remains checksum-addressed in the source release.